Mumbai, Baltimore, August 16, 2023: Global pharma major Lupin Limited (Lupin) today announced the launch of Tiotropium Bromide Inhalation Powder, 18 mcg/capsule, for the treatment of chronic obstructive pulmonary disease (COPD) in the US. Tiotropium Bromide Inhalation Powder, 18 mcg/capsule is a generic equivalent of Spiriva® HandiHaler® (Tiotropium Bromide Inhalation Powder), 18 mcg/capsule of Boehringer Ingelheim Pharmaceuticals, Inc.
With this launch, Lupin introduces an alternative to combat COPD, a condition impacting over 15 million adults in the US and ranked as the fourth leading cause of death in the country. By extending enhanced accessibility to cutting-edge products, Lupin actively contributes to alleviating the burden of COPD for patients across the nation. Read more >
